| アブストラクト | Glucagon-like peptide-1 receptor agonists are increasingly prescribed for type 2 diabetes mellitus and obesity, with expanding therapeutic applications. Although gastrointestinal adverse events are the most recognized toxicities, cutaneous adverse events constitute a large burden of total adverse reactions. To review the prevalence, clinical features, mechanisms, and management of nonimmunologic injection site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists. A review of clinical trials, pharmacovigilance studies, and case reports and series was performed. In addition, adverse event reports for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide were extracted from the United States Food and Drug Administration Adverse Event Reporting System. Injection-site events were combined with skin-related adverse events to generate an adjusted skin and injection-site reactions category for comparison across agents. Among 442,567 Food and Drug Administration Adverse Event Reporting System reports, 137,412 (31.0%) involved skin and injection-site reactions, representing the third most frequently reported adverse event category. Exenatide demonstrated the highest proportion of skin and injection-site reports (53.1%), followed by dulaglutide (33.5%), tirzepatide (32.6%), liraglutide (17.1%), semaglutide (12.2%), and lixisenatide (6.9%). Common reactions included pain, bleeding, erythema, bruising, mass, pruritus, and swelling. Additional adverse events included dysesthesias, nodules, granulomatous reactions, bruising, and hyperhidrosis. Most reactions were mild to moderate and generally managed symptomatically without requiring treatment discontinuation. Nonimmunologic cutaneous adverse events comprise a substantial proportion of reported glucagon-like peptide-1 receptor agonists-associated adverse events with differing rates among individual agents. Recognition of these reactions and appropriate supportive management may improve patient outcomes. Prospective studies are needed to better define their adverse event risk rates, mechanisms, and optimal management strategies. |
|---|
| 組織名 | The Ohio State University Wexner Medical Center, Department of Hospital Medicine,;Columbus, Ohio, USA. Electronic address: dareenelgindi@gmail.com.;Cook County John H. Stroger Hospital Department of Dermatology, Chicago,;Illinois, USA. |
|---|
